Detalhe da pesquisa
1.
Metabolism-driven in vitro/in vivo disconnect of an oral ERÉ VHL-PROTAC.
Commun Biol
; 7(1): 563, 2024 May 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-38740899
2.
The Next-Generation Oral Selective Estrogen Receptor Degrader Camizestrant (AZD9833) Suppresses ER+ Breast Cancer Growth and Overcomes Endocrine and CDK4/6 Inhibitor Resistance.
Cancer Res
; 83(23): 3989-4004, 2023 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37725704
3.
Discovery of a Potent and Orally Bioavailable Zwitterionic Series of Selective Estrogen Receptor Degrader-Antagonists.
J Med Chem
; 66(4): 2918-2945, 2023 02 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-36727211
4.
From libraries to candidate: the discovery of new ultra long-acting dibasic ß2-adrenoceptor agonists.
Bioorg Med Chem Lett
; 22(1): 689-95, 2012 Jan 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-22079756
5.
Genome engineering for estrogen receptor mutations reveals differential responses to anti-estrogens and new prognostic gene signatures for breast cancer.
Oncogene
; 41(44): 4905-4915, 2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-36198774
6.
Design driven HtL: The discovery and synthesis of new high efficacy ß2-agonists.
Bioorg Med Chem Lett
; 21(13): 4027-31, 2011 Jul 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-21652207
7.
Discovery of AZD9833, a Potent and Orally Bioavailable Selective Estrogen Receptor Degrader and Antagonist.
J Med Chem
; 63(23): 14530-14559, 2020 12 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32910656
8.
Tricyclic Indazoles-A Novel Class of Selective Estrogen Receptor Degrader Antagonists.
J Med Chem
; 62(3): 1593-1608, 2019 02 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-30640465
9.
Combined Inhibition of mTOR and CDK4/6 Is Required for Optimal Blockade of E2F Function and Long-term Growth Inhibition in Estrogen Receptor-positive Breast Cancer.
Mol Cancer Ther
; 17(5): 908-920, 2018 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29483206
10.
Discovery of potent and selective adamantane-based small-molecule P2X(7) receptor antagonists/interleukin-1beta inhibitors.
J Med Chem
; 50(24): 5882-5, 2007 Nov 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-17963373
11.
Activating ESR1 Mutations Differentially Affect the Efficacy of ER Antagonists.
Cancer Discov
; 7(3): 277-287, 2017 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-27986707
12.
AZD9496: An Oral Estrogen Receptor Inhibitor That Blocks the Growth of ER-Positive and ESR1-Mutant Breast Tumors in Preclinical Models.
Cancer Res
; 76(11): 3307-18, 2016 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27020862
13.
Inhibition of PI3Kß signaling with AZD8186 inhibits growth of PTEN-deficient breast and prostate tumors alone and in combination with docetaxel.
Mol Cancer Ther
; 14(1): 48-58, 2015 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-25398829
14.
Discovery of AZD3199, An Inhaled Ultralong Acting ß2 Receptor Agonist with Rapid Onset of Action.
ACS Med Chem Lett
; 5(4): 416-21, 2014 Apr 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-24900851
15.
Agonist-specific patterns of beta 2-adrenoceptor responses in human airway cells during prolonged exposure.
Br J Pharmacol
; 158(1): 169-79, 2009 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-19558544
16.
Hit-to-Lead studies: the discovery of potent adamantane amide P2X7 receptor antagonists.
Bioorg Med Chem Lett
; 13(22): 4047-50, 2003 Nov 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-14592505